Skip to Main Content

Paper Details

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
JAMA Oncol
245
2017
BRCA1, BRCA2, BRCA2 mutation, CD8, CD8+, CD8+ TIL, CD8+ TILs, CD8+ Tumor-Infiltrating Lymphocytes, Cytotoxic CD8+ tumor-infiltrating lymphocytes, HGSOC, HGSOCs, High-Grade Serous Ovarian Cancer, Ovarian Tumor, Participants, Patients, TILs, cancer, endometrioid and mucinous carcinomas, epithelial ovarian cancer, high-grade serous ovarian carcinomas, patients, person, tumor, women
Author NameAffiliation
Ellen L GoodeMayo Clinic
Aleksandra Gentry-MaharajGynaecological Cancer Research Centre, Institute for Women's Health, University College London
Aleksandra Gentry-MaharajGynaecological Cancer Research Centre, Institute for Women's Health, University College London
Aleksandra To??oczko-GrabarekInternational Hereditary Cancer Center, Pomeranian Medical University
Ana OsorioSpanish National Cancer Research Centre (CNIO)
Ana OsorioInstituto de Salud Carlos III
Bo GaoThe Westmead Institute for Medical Research, The University of Sydney
Bo GaoThe Crown Princess Mary Cancer Centre, Westmead Hospital, The University of Sydney
Brenda Y HernandezCancer Center, University of Hawaii
Brooke L FridleyMoffitt Cancer Center
Bryan M McCauleyMayo Clinic
Catherine J KennedyThe Westmead Institute for Medical Research, The University of Sydney
Catherine J KennedyWestmead Hospital
Chen WangMayo Clinic
Chloe KarpinskyjGynaecological Cancer Research Centre, Institute for Women's Health, University College London
Esther HerpelTissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Germany and Institute of Pathology, University of Heidelberg
Jan LubinskiInternational Hereditary Cancer Center, Pomeranian Medical University
Jan LubinskiInternational Hereditary Cancer Center, Pomeranian Medical University
Janusz MenkiszakPomeranian Medical University
Jennifer AlsopUniversity of Cambridge
Jenny LesterSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Jes??s Garc??a-DonasHM Hospitales - Centro Integral Oncologico HM Clara Campal
Jos?? PalaciosHospital Universitario Ramon y Cajal. IRYCIS. Universidad de Alcala
Joseph H RothsteinIcahn School of Medicine at Mount Sinai
Maria P IntermaggioUniversity of New South Wales
Maria P IntermaggioUniversity of New South Wales
Martin WidschwendterGynaecological Cancer Research Centre, Institute for Women's Health, University College London
Mercedes Jimenez-LinanAddenbrookes Hospital
Naveena SinghBarts Health National Health Service Trust
Oleg OszurekInternational Hereditary Cancer Center, Pomeranian Medical University
Paul HarnettThe Westmead Institute for Medical Research, The University of Sydney
Paul HarnettThe Crown Princess Mary Cancer Centre, Westmead Hospital, The University of Sydney
Hans-Peter SinnInstitute of Pathology, Heidelberg University Hospital
Raghwa SharmaWestmead Hospital, The University of Sydney
Raghwa SharmaUniversity of Western Sydney at Westmead Hospital
Sandra OrsulicSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Sharon E JohnattyQIMR Berghofer Medical Research Institute
Teri A LongacreStanford University
Weiva SiehIcahn School of Medicine at Mount Sinai
Alice S WhittemoreStanford University School of Medicine
Anna DeFazioThe Westmead Institute for Medical Research, The University of Sydney
Anna DeFazioWestmead Hospital
Anna DeFazioThe Westmead Institute for Medical Research, The University of Sydney
Anna DeFazioWestmead Hospital
Beth Y KarlanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Cyril B GilksVancouver General Hospital and University of British Columbia
David D L BowtellPeter MacCallum Cancer Centre
David D L BowtellThe Garvan Institute
David D L Bowtellthe University of Melbourne
David D L BowtellPeter MacCallum Cancer Centre
  • 1 - 50

Datasets